Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Skin cancer research gets $1 mil.

This article was originally published in The Rose Sheet

Executive Summary

National Cancer Institute grants $1 mil. to a University of Connecticut research team to develop a topical treatment that prevents and repairs sun damage leading to skin cancer, UConn states in Nov. 8 release. Researchers say they will develop the treatment using alpha-melanocyte stimulating hormone (alpha-MSH), which increases skin pigmentation to reduce UV penetration and "repair precancerous damage that UV rays do to skin cell DNA." Melanoma, the deadliest form of skin cancer, only occurs in 8% of skin cancer cases, but "causes almost all skin cancer deaths, and its incidence is rising at the rate of 4% per year," according to the statement. "The impact of this grant is potentially tremendous," study leader Zalfa Abdel-Malek, PhD, said. The treatment would be especially beneficial to fair-skinned people and others who generally carry a high risk for skin cancer, Abdel-Malek added...



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts